Changing streptococci and prospects for the global eradication of rheumatic fever

Perspectives in Biology and Medicine

Volumn 40, Issue 2, 1997, Pages 165-187

  Stollerman, Gene H ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

M PROTEIN; STREPTOCOCCUS VACCINE;

HEMOLYTIC STREPTOCOCCUS; HUMAN; NECROTIZING FASCIITIS; PRIORITY JOURNAL; PYODERMA; REVIEW; RHEUMATIC FEVER; SEPTIC SHOCK; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; VACCINATION;

EID: 0030663559     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.1997.0044     Document Type: Review

References (115)

1. STOLLERMAN, G. H. The nature of rheumatogenic streptococci. Mt. Sinai J. Med. 63:144-158, 1996.
2. SCHOTMULLER, H. Die Artunterscheindung der fur den menschen pathogenen Streptokokken durch blutagar. Munchen Med. Wochenschr. 1:849, 909, 1903.
3. SCHICK, B. Uber die Nachkrankheiten des Scharlach. Jahrb Kinderheik (Berlin) 65:132-175, 1907.
4. DICK, G. F., and DICK, G. H. The etiology of scarlet fever. JAMA 82:301-302, 1924.
5. DOCHEZ, A. R. Etiology of scarlet fever. Harvey Lectures (1924-25) 20:131-151, 1926.
6. GRIFFITH, F. Types of hemolytic streptococci in relation to scarlet fever. J. Hygiene 25:385-397, 1926.
7. LANCEFIELD, R. C. Specific relationship of cell composition to biological activity of hemolytic streptococci. Harvey Lectures (1940-41) 35:251, 1941.
8. WILSON, A. T. The relative importance of the capsule and the M antigen in determining colony form of group A steptococci. J. Exp. Med. 109:257, 1959.
9. TODD, E. W. Antigenic streptococcal hemolysin. J. Exp. Med. 55:267-280, 1932.
10. COBURN, A. F. The factor of infection in the rheumatic state. Baltimore: Williams & Wilkins, 1931.
11. COBURN, A. F., and MOORE, L. V. The prophylactic use of sulfanilamide in streptococcal respiratory infections, with special reference to rheumatic fever. J. Clin. Invest. 18:147-155, 1939.
12. RAMMELKAMP, C. H.; DENNY, F. W.; and WANNAMAKER, L. W. Studies on the epidemiology of rheumatic fever in the armed services. In Rheumatic Fever, edited by L. THOMAS. Minneapolis: Univ. of Minnesota Press, 1952. 72-89.
13. STOLLERMAN, G. H., and RUSOFF, J. R. Prophylaxis against group A streptococcal infections in rheumatic fever patients: Use of a new repository penicillin. JAMA 150:1571-1575, 1952.
14. STOLLERMAN, G. H.; RUSOFF, J. H.; and HIRSHFIELD, I. Prophylaxis against group A streptococci in rheumatic fever: The use of single monthly injections of benzathine penicillin G. N. Engl. J. Med. 252:787-792, 1955.
15. WOOD, H. F.; STOLLERMAN, G. H.; FEINSTEIN, A. R.; et al. A controlled study of three methods of prophylaxis against streptococcal infection in a population of rheumatic children. N. Engl. J. Med. 106:345-356, 1957.
16. CHAMOVITZ, R.; CATANZARO, F. J.; STETSON, C. A.; et al. Prevention of rheumatic fever by treatment of previous streptococcal infections: 1. Evaluation of benzathine penicillin G. N. Engl. J. Med. 251:466-471, 1954.
17. FRANK, P. F.; STOLLERMAN, G. H.; and MILLER, L. F. Protection of a military population from rheumatic fever. JAMA 193:775-783, 1965.
18. NELSON, J. D., and MOHS, E. A. Socioeconomic and behavioral residua of antibiotic therapy in infancy and childhood. In New Trends in Antibodies, edited by G. GERALDONI GRASSI G. and L. D. SABBATH. New York: Elsevier/ N. Holland Biomedical Press, 1981.
19. United Kingdom/United States Joint Report. The natural history of rheumatic fever and rheumatic heart disease: Ten-year report of a cooperative clinical trial of ACTH, cortisone and aspirin. Circ. 32:457-476, 1965.
20. TARANTA, A., and STOLLERMAN, G. H. The relationship of Sydenham's chorea to infection with group A streptococci. Am. J. Med. 20:170-175, 1956.
21. TARANTA, A. Relation of isolated recurrences of Sydenham's chorea to preceding streptococcal infections. N. Engl. J. Med. 260:1204-1210, 1959.
22. STOLLERMAN, G. H.; SIEGEL, A. C.; and JOHNSON, E. E. Variable epidemiology of streptococcal disease and the changing pattern of rheumatic fever. Mod. Concepts Cardiov. Dis. 34:45-48, 1965.
23. JOHNSON, J. C., and STOLLERMAN, G. H. Nephritogenic streptococci. Ann. Rev. Med. 20:315-322, 1969.
24. WANNAMAKER, L. W. Medical progress: Differences between streptococcal infections of the throat and of the skin. N. Engl. J. Med. 282:23, 78; 1970.
25. WANNAMAKER, L. W. The chain that links the heart to the throat. Circ. 48: 9, 1973.
26. STOLLERMAN, G. H. Factors determining the attack rate of rheumatic fever. JAMA 177:823, 1961.
27. AYOUB, E. A.; BARRETT, B. J.; MACLAREN, N. K.; et al. Association of class II human histocompatibility leucocyte antigens with rheumatic fever. J. Clin. Invest. 77:2019, 1986.
28. ZABRISKIE, J. B.; LAVENCHY, D.; WILLIAMS, R. C. JR.; et al. Rheumatic fever-associated B cell alloantigens as identified by monoclonal antibodies. Arthritis Rheumatism 28:1047, 1985.
29. STETSON, C. A. The relation of antibody response to rheumatic fever. In Streptococcal Infections, edited by M. MCCARTY. New York: Columbia Univ. Press, 1954. 208-218.
30. SIEGEL, A. C.; JOHNSON, E. E.; and STOLLERMAN, G. H. Controlled studies of streptococcal pharyangitis in a pediatric population: 1. Factors related to the attack rate. N. Engl. J. Med. 265:559-566, 1961.
31. VALKENBURG, H. A.; GOSLINGS, W. R. O.; BOTS, A. W.; et al. Attack rate of streptococcal pharyngitis, rheumatic fever and glomerulonephritis in the general population: II. The epidemiology of streptococcal pharyngitis in one village during a two-year period. N. Engl. J. Med. 268:694-701, 1963.
32. COBURN, A. F., and PAULI, R. H. Studies on the immune response of the rheumatic subject and its relationship to activity of the rheumatic process: IV. Characteristics of strains of hemolytic streptococcus, effective and non-effective in initiating rheumatic activity. J. Clin. Invest. 14:755-762, 1935.
33. KUTTNER, A. G., and KRUMWIEDE, E. Observations on the effect of streptococcal upper respiratory infections on rheumatic children: A three-year study. J. Clin. Invest. 20:273-287, 1941.
34. BLOOMFIELD, A. L., and RANTZ, L. H. An outbreak of streptococci septic sore throat in an army camp: Clinical and epidemiologic observations. JAMA 121:315-319, 1943.
35. DUDDING, B. A.; DILLON, H. C.; WANNAMAKER, L. W.; et al. Postepidemic surveillance studies of a food-borne epidemic of streptococcal pharyngitis at the United States Air Force Academy. J. Infect. Dis. 120:225-236, 1969.
36. STOLLERMAN, G. H. Nephritogenic and rheumatogenic group A streptococci. J. Infect. Dis. 120:258-263, 1969.
37. RAMMELKAMP, C. H. JR.; WEAVER, R. S.; and DINGLE, J. H. Significance of the epidemiological differences between acute nephritis and acute rheumatic fever. Trans. Assoc. Am. Phys. 65:168-175, 1952.
38. PARKER, M. T.; BASSET, D. C. J.; MAXTED, W. R.; et al. Acute glomerulonephritis in Trinidad: Serological typing of group A. streptococci. J. Hyg. 66: 657-675, 1968.
39. TOP, F. H.; WANNAMAKER, L. W.; MAXTED, W. R.; et al. M antigens among group A streptococci isolated from skin lesions. J. Exp. Med. 126:667-685, 1967.
40. POTTER, E. V.; SVARTMAN, M.; MOHAMMED, I.; et al. Tropical acute rheumatic fever and associated streptococcal infections compared with concurrent acute glomerulonephritis. J. Pediatr. 92:325, 1978.
41. WIDDOWSON, J. P.; MAXTED, W. R.; and GRANT, D. L. The production of opacity in serum by group A streptococci and its relationship with the presence of M antigen. J. Gen. Microbiol. 61:343-353, 1970.
42. WIDDOWSON, J. P.; MAXTED, W. R.; GRANT, D. L.; et al. The relationship between M antigen and opacity factor in group A streptococci. J. Gen. Microbiol. 65:69-80, 1971.
43. MAXTED, W. R., and VALKENBURG, H. A. Variation in the M-antigen of group A streptococci. J. Med. Microbiol. 2:199-210; 1969.
44. BISNO, A. L.; PEARCE, I. A.; WALL, H. P.; et al. Contrasting epidemiology of acute rheumatic fever and acute glomerulonephritis: Nature of the Antecedent streptococcal infection. N. Engl. J. Med. 283:561-565, 1970.
45. LAND, M., and BISNO, A. L. Acute rheumatic fever: A vanishing disease in suburbia. JAMA 249:895, 1983.
46. STOLLERMAN, G. H. Global changes in group A streptococcal diseases and strategies for their prevention. Adv. Intern. Med. 27:373, 1982.
47. HOLMBERG, S. D., and FAICH, F. A. Streptococcal pharyngitis and acute rheumatic fever in Rhode Island. JAMA 250:2307-2312, 1983.
48. STOLLERMAN, G. H. Rheumatogenic group A streptococci and the return of rheumatic fever. Adv. Intern. Med. 35:1-26, 1990.
49. VEASY, L. G.; WIEDMEIER, S. E.; GARTH, S.O.; et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N. Engl. J. Med. 316:421, 1987.
50. Centers for Disease Control. Acute rheumatic fever - Utah. MMWR 36: 108, 1987.
51. KAPLAN, E. L.; JOHNSON, D. R.; and CLEARY, P. P. Group A streptococcal serotypes isolated from patients and sibling contacts during the resurgence of rheumatic fever in the United States in the mid-1980s. J. Infect. Dis. 159:101-103, 1989.
52. SCHWARTZ, B.; FACKLAM, R. R.; and BREIMAN, R. F. Changing epidemiology of group A streptococcal infection in the USA. Lancet 336:1167-1171, 1990.
53. JOHNSON, D. R.; STEVENS, D. L.; and KAPLAN, E. L. Epidemiologic analysis of group A streptococcal serotypes associated with severe system infections, rheumatic fever or uncomplicated pharyngitis. J. Infect. Dis. 166: 374-382, 1992.
54. CONE, L. A.; WOODARD, D. R.; SCHLIEVERT, P. M.; et al. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N. Engl. J. Med. 317:146, 1987.
55. KIM, Y. B., and WATSON, D. W. Streptococcal exotoxins: Biological and pathological properties. In Streptococci and Streptococcal Diseases, edited by L. W. WANNAMAKER and J. M. MATSEN. New York: Academic Press, 1972.
56. STOLLERMAN, G. H. The historical role of the Dick test. JAMA 250:3097-3099, 1983.
57. STEVENS, D. L.; TANNER, M. H.; WINSHIP, J.; et al. Severe group A streptococcal infections associated with toxic shock-like syndrome and scarlet fever toxin A. N. Engl. J. Med. 321:1-7, 1989.
58. HOGE, C. W.; SCHWARTZ, B.; TALKINGTON, D. F.; et al. The changing epidemiology of invasive group A streptococcal infections and the consequence of streptococcal toxic shock-like syndrome: A retrospective population-based study. JAMA 269:384-389, 1993.
59. HOLM, S. E.; NORRBY, A.; BERGHOLM, A. M.; and NORGREN, M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J. Infect. Dis. 166:31-37, 1992.
60. NORRBY-TEGLUND, A.; NEWTON, D.; KOTB, M.; et al. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect. Immun. 62: 5227-5233, 1994.
61. IWASAKI, M.; IGARASHI, H.; HINUMA, Y.; and YUTSUDO, T. Cloning, characterization and overexpression of a Streptococcus pyogenes gene encoding a new type of mitogenic factor. FEBS Lett. 331:187-192, 1993.
62. PAUL, J. Comparative rates of scarlet fever and rheumatic fever in the U.S. Navy, 1942-1945. In Epidemiology of Rheumatic Fever. New York: American Heart Association, 1957.
63. BEACHEY, E. H., and STOLLERMAN, G. H. Mediation of cytotoxic effects of streptococcal M protein by nontype specific antibody in human sera. J. Clin. Invest. 52:2563-2570, 1973.
64. MOLLICK, J. A.; MILLER, G. G.; MUSSER, J. M.; et al. A novel superantigen isolated from pathogenic strain of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxin B and C. J. Clin. Invest. 92: 710-717, 1993.
65. WATANABE-OHNISHI, R.; AELION, J.; LEGROS, L.; et al. Characterization of unique human TCR V-beta specificities for a family of streptococcal superantigens represented by rheumatogenic serotypes of M protein. J. Immunol. 152:2066-2073, 1994.
66. HACKETT, S. P., and STEVENS, D. L. Superantigens associated with staphylococcal and streptococcal toxic shock syndrome are potent inducers of tumor necrosis factor β synthesis. J. Infect. Dis. 168:232-235, 1993.
67. LEUNG, D. Y. M., et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J. Clin. Invest. 96:2106, 1995.
68. BISNO, A. L., and STEVENS, D. L. Streptococcal infections of skin and soft tissues. N. Engl. J. Med. 334:240-245, 1995.
69. KAPLAN, E. L. Global assessment of rheumatic fever and rheumatic heart disease at the close of the century. Circulation 88:1964-1972, 1993.
70. STOLLERMAN, G. H., and EKSTEDT, R. D. Long chain formation by strains of group A streptococci in the presence of homologous antiserum: a type-specific reaction. J. Exper. Med. 106:345-356, 1957.
71. ROTHBARD, S., and WATSON, R. F. Variation occurring in group A streptococci during human infection: Progressive loss of M substance correlated with increasing susceptibility to bacteriostasis. J. Exp. Med. 87:521-533, 1948.
72. WIDDOWSON, J. P.; MAXTED, W. R.; NOTLEY, C. M.; et al. Antibody responses in man to infection with different serotypes of group A streptococci. J. Med. Microbiol. 7:483, 1974.
73. STOLLERMAN, G. H.; RYTEL, M.; and ORTIZ, J. Accessory plasma factors involved in the bactericidal test for type-specific antibody to group A streptococci: II. Human plasma cofactor(s) enhancing opsonization of encapsulated organisms. J. Exper. Med. 117:1-17, 1963.
74. STOLLERMAN, G. H. Rheumatic Fever and Streptococcal Infection. New York: Grune and Stratton, 1975.
75. BISNO, A. L. The concept of rheumatogenic and non-rheumatogenic group A streptococci. In Streptococcal Diseases and the Immune Response, edited by S. E. READ and J. B. ZABRISKI. New York: Academic Press, 1980, 789.
76. BISNO, A. L.; PEARCE, I. A.; and STOLLERMAN, G. H. Streptococcal infections that fail to cause recurrences of rheumatic fever. J. Infect. Dis. 136: 278, 1977.
77. BERRIOS, X.; DELCAMPO, E.; GUZMAN, B.; and BISNO, A. L. Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults: A prospective study. Ann. Intern. Med. 118:401-406, 1993.
78. FOX, E. N.; PACHMAN, L. M.; WITTNER, M. K.; et al. Primary immunization of infants and children with group A streptococcal M protein. J. Infect. Dis. 120:598-604, 1969.
79. SCHMIDT, W. C. Type specific antibody formation in man following injection of streptococcal M protein. J. Infect. Dis. 106:250-255, 1960.
80. POTTER, E. V.; STOLLERMAN, G. H.; and SIEGEL, A. C. Recall of type specific antibodies in man by injections of streptococcal cell walls. J. Clin. Invest. 41:301-310, 1962.
81. STOLLERMAN, G. H. Prospects for a vaccine against group A streptococci: The problem of the immunology of M proteins. Arthritis Rheum. 10:245-255, 1967.
82. KAPLAN, M. H., and SVEC, K. H. Immunologic relation of streptococcal and tissue antigens: III. Presence in human sera of streptococcal antibody cross reactive with heart tissue - Association with streptococcal infection, rheumatic fever and glomerulonephritis. J. Exp. Med. 119;651-666, 1964.
83. ZABRISKIE, J. B., and FREIMER, E. H. An immunological relationship between the Group A streptococcus and mammalian muscle. J. Exp. Med. 124: 661-678, 1966.
84. BEACHEY, E. H., and OFEK, I. Epithelial cell binding of group A streptococci by lipoteichoic acid on fimbriae denuded of M protein. J. Exp. Med. 143:759, 1976.
85. BEACHEY, E. H.; STOLLERMAN, G. H.; CHIANG, E. Y.; et al. Purification and properties of M protein extracted from group A streptococci with pepsin: Covalent structure of the amino terminal region of type 24M antigen. J. Exp. Med. 145:1469, 1977.
86. BEACHEY, E. H.; STOLLERMAN, G. H.; JOHNSON, R. H.; et al. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J. Exper. Med. 150:862-877, 1979.
87. CUNNINGHAM, M. W.; MCCORMACK, J. M.; FENDERSON, P. G.; et al. Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. J. Immunol. 143:2677, 1989.
88. KRISHER, K., and CUNNINGHAM, M. W. Myosin: A link between streptococci and heart. Science 227:413-415, 1985.
89. DALE, J. B., and BEACHEY, E. H. Protective antigenic determinant of streptococcal M protein shared with sarcolemmal membrane protein of human heart. J. Exp. Med. 156:1165-1176, 1982.
90. DALE, J. B., and BEACHEY, E. H. Multiple heart-cross-reactive epitopes of streptococcal M proteins. J. Exp. Med. 161:113-176, 1985.
91. PHILLIPS, G. N.; FLICKER, P. F.; COHEN, C.; et al. Streptococcal M protein: Alpha-helical coiled-coil structure and arrangements on the cell surface. Proc. Nat. Acad. Sci. USA 78:4689, 1981.
92. MANJULA, B. N., and FISCHETTI, V. A. Tropomyosin-like seven residue periodicity in three immunologically distinct streptococcal M proteins and its implications for the antiphagocytic property of the molecule. J. Exp. Med. 151:695, 1980.
93. HOLLINGSHEAD, S. K.; FISCHETTI, V. A.; and SCOTT, J. R. Complete nucleotide sequence of type 6M protein of the group A streptococcus: Repetitive structure and membrane anchor. J. Biol. Chem. 261:1677-1686, 1986.
94. BESSEN, D.; JONES, K. F.; and FISCHETTI, V. A. Evidence for two distinct classes of streptococcal M-protein and their relationship to rheumatic fever. J. Exp. Med. 169:269-283, 1989.
95. BESSEN, D. E.; VEASY, L. G.; HILL, H. R.; AUGUSTINE, N. H.; FISCHETTI, V. A. Serologic evidence for a Class I group A streptococcal infection among rheumatic fever patients. J. Infect. Dis. 172:1608-1611, 1995.
96. FISCHETTI, V. A.; JONES, K. F.; HOLLINGSHEAD, S. K.; and SCOTT, J. R. Structure, function and genetics of streptococcal M protein. Rev. Infect. Dis. 10(Suppl 2):S356-S359, 1988.
97. DALE, J. B., and BEACHEY, E. H. Sequence of myosin-cross-reactive epitopes of streptococcal M protein. J. Exp. Med. 164:1785-1790, 1986.
98. DALE, J. B.; SEYER, J. M.; and BEACHEY, E. H. Type-specific immunogenicity of a chemically synthesized peptide fragment of type 5 streptococcal M protein. J. Exp. Med. 158:1727-1732, 1983.
99. BAIRD, R. W.; BRONZE, M. S.; KRAUS, W.; et al. Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium. J. Immunol. 146:3132-3137, 1991.
100. BRONZE, M. S., and DALE, J. B. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. J. Immun. Col. 151: 2820-2828, 1993.
101. Jones Criteria (revised) for guidance in the diagnosis of rheumatic fever. Circulation 32:664-668, 1965.
102. FEINSTEIN, A. R.; WOOD, H. F.; SPAGNUOLO, M.; et al. Rheumatic fever in children and adolescents: VII. Cardiac changes and sequelae. Ann. Intern. Med. 60(suppl 5):87-123, 1964.
103. 2-terminal sequences of types 5, 6 and 24M proteins synthesized in tandem. J. Exp. Med. 166:647-656, 1987.
104. DALE, J. B.; SIMMONS, M.; CHIANG, E. C.; and CHIANG, E. Y. Recombinant octavalent group A streptococcal vaccine. Vaccine 1996; in press.
105. DALE, J. B. 1996. Type-specific, multivalent group A streptococcal M protein vaccines. In Streptococcal Infections. D. L. STEVENS and E. L. KAPLAN (eds.), New York, Oxford University Press (In Press).
106. FISCHETTI, V. A. Protection against group A streptococcal infection. Streptococcal Infections. Ibid.
107. BESSEN, D., and FISCHETTI, V. A. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A steptococci. Infect. Immun. 565:2666-2672, 1988.
108. DALE, J. B., and CHIANG, E. C. Intranasal immunization with recombinant group A streptococcal M fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections. J. Infect. Dis. 171:1038-1041, 1995.
109. HARTAS, J.; GOODFELLOW, A. M.; CURRIE, B. S.; and SRIPRAKASH, K. S. Characterization of group A streptococcal isolates from topical Australia with high prevalence of rheumatic fever: Probing for signature sequences to identify members of the family of serotype 5. Microb. Path. 18:345-354, 1995.
110. DAJANI, A. S.; BISNO, A. L.; CHUNG, K. J.; et al. Prevention of rheumatic fever: A statement for health professionals by the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Circulation 78:1082-1086, 1988.
111. RAZ, R.; ELCHANAN, G.; COLODNER, R.; et al. Penicillin V twice daily vs. four times daily in the treatment of streptococcal pharyngitis. Inf. Dis. Clin. Prac. 4:50-54, 1995.
112. PICHERERO, M. E. Cephalosporins are superior to penicillin for the treatment of tonsillopharyngitis: Is the difference worth it? Pediatr. Infect. Dis. J. 123:268-274, 1993.
113. STOLLERMAN, G. H. Penicillin for streptococcal pharyngitis: Has anything changed? Hosp. Prac. 30:80-83, 1995.
114. KRAUSE, R. M., and RAMMELKAMP, C. H., JR. Studies of the carrier state following infection with group A streptococci: II. Infectivity of streptococci isolated during acute pharyngitis and during the carrier state. J. Clin. Invest. 41:575-578, 1962.
115. STOLLERMAN, G. H. The global impact of penicillin: Then and now. Mt. Sinai J. Med. 60(2):112-119, 1993.